EP1446014A4 - Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques - Google Patents

Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques

Info

Publication number
EP1446014A4
EP1446014A4 EP02800391A EP02800391A EP1446014A4 EP 1446014 A4 EP1446014 A4 EP 1446014A4 EP 02800391 A EP02800391 A EP 02800391A EP 02800391 A EP02800391 A EP 02800391A EP 1446014 A4 EP1446014 A4 EP 1446014A4
Authority
EP
European Patent Office
Prior art keywords
wlds
gene
introduction
prevention
neurological diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02800391A
Other languages
German (de)
English (en)
Other versions
EP1446014A2 (fr
Inventor
Jonathan D Glass
Mark M Rich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of EP1446014A2 publication Critical patent/EP1446014A2/fr
Publication of EP1446014A4 publication Critical patent/EP1446014A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02800391A 2001-10-01 2002-10-01 Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques Withdrawn EP1446014A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32635401P 2001-10-01 2001-10-01
US326354P 2001-10-01
PCT/US2002/031078 WO2003029414A2 (fr) 2001-10-01 2002-10-01 Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques

Publications (2)

Publication Number Publication Date
EP1446014A2 EP1446014A2 (fr) 2004-08-18
EP1446014A4 true EP1446014A4 (fr) 2004-12-08

Family

ID=23271854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02800391A Withdrawn EP1446014A4 (fr) 2001-10-01 2002-10-01 Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques

Country Status (3)

Country Link
EP (1) EP1446014A4 (fr)
CA (1) CA2462632A1 (fr)
WO (1) WO2003029414A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503069A (ja) * 2002-09-25 2006-01-26 ジョージア テック リサーチ コーポレイション 慢性神経疾患におけるケトアミド阻害剤
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator
WO2019009979A1 (fr) * 2017-07-06 2019-01-10 The Medical College Of Wisconsin, Inc. Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064907A2 (fr) * 2000-03-02 2001-09-07 Incyte Genomics, Inc. Enzymes metabolisant les lipides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064907A2 (fr) * 2000-03-02 2001-09-07 Incyte Genomics, Inc. Enzymes metabolisant les lipides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CONFORTI L ET AL: "A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11377 - 11382, XP002953257, ISSN: 0027-8424 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, COLEMAN M P ET AL: "Protecting axons: The molecular basis of slow Wallerian degeneration", XP002299951, Database accession no. PREV200200038753 *
DATABASE GENBANK 2 October 2000 (2000-10-02), CONFORTI; ET AL: "Mus musculus UFD2/D4COLE1E fusion protein mRNA", XP002953260, retrieved from GENBANK Database accession no. AF260924 *
FERNANDO S ET AL: "Characterization of the human homologue of a candidate gene for slow Wallerian degeneration", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, no. SUPPLEMENT 2, October 2000 (2000-10-01), pages 178, XP002953261, ISSN: 0002-9297 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001, pages 2623, ISSN: 0190-5295 *
WANG M-S ET AL: "Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 59, no. 7, July 2000 (2000-07-01), pages 599 - 606, XP002953258, ISSN: 0022-3069 *
WANG M-S ET AL: "The gene for low Wallerian degeneration (WldS) is also protective against vincristine neuropathy", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 8, 20 December 2000 (2000-12-20), pages 155 - 161, XP002953259, ISSN: 0969-9961 *

Also Published As

Publication number Publication date
CA2462632A1 (fr) 2003-04-10
EP1446014A2 (fr) 2004-08-18
WO2003029414A3 (fr) 2003-12-18
WO2003029414A2 (fr) 2003-04-10

Similar Documents

Publication Publication Date Title
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
IL162183A0 (en) Polymer-lipid delivery vehicles and methods for the preparation thereof
AU2002330914A1 (en) A process for enhancing the body and taste of malt beverages
AU2002352799A8 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
EP1448586A4 (fr) Procedes therapeutiques pour vehicules d'administration d'acides nucleiques
AU2003253014A8 (en) Method for the diagnosis and differential diagnosis of neurological diseases
HK1079220A1 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases cd83
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002246580A1 (en) Antisense imaging of gene expression of the brain in vivo
EP1680145A4 (fr) Methodes et compositions pour le traitement de maladies neurologiques
AU1020201A (en) Human sphingosine kinase gene
AU2002319717A1 (en) Mutant nurr1 gene in parkinson's disease
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
EP1537790A4 (fr) Boisson chocolatee et son procede de production
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
EP1446014A4 (fr) Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques
AU2002355857A1 (en) Gene associated with bone disorders
EP1163340A4 (fr) Compositions et methodes de modification de l'expression genique
EP1578908A4 (fr) Gene humain de la schizophrenie
AU2002239531A1 (en) Differential gene expression in specific regions of the brain in neurodegenerative diseases
AU2002312624A8 (en) Drug metabolizing enzymes
EP1370138A4 (fr) Therapie genique pour tissus neurologiques
EP1439225A4 (fr) Promoteur du gene dr5 et promoteur du gene siah-1
AU2001264719A8 (en) Haplotypes of the aanat gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040424

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041027

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/00 B

Ipc: 7A 61K 31/713 B

Ipc: 7A 61K 38/17 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12N 15/62 B

Ipc: 7C 07K 19/00 B

Ipc: 7C 07K 14/47 B

Ipc: 7C 12N 15/12 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 12N 15/74 B

Ipc: 7C 12N 15/70 B

Ipc: 7C 12N 15/63 B

Ipc: 7C 12N 15/09 B

Ipc: 7C 12N 15/00 B

Ipc: 7A 61K 31/70 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 01N 43/04 B

Ipc: 7A 01N 65/00 B

Ipc: 7A 01N 63/00 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060503